Clinical Trial Update: Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating DaxibotulinumtoxinA for Benign Essential Blepharospasm and Hemifacial Spasm is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Essential Blepharospasm
• Hemifacial Spasm

Drugs mentioned

• DAXXIFY (daxibotulinumtoxinA-lanm)

Snippet

Sponsor: Montefiore Medical Center | Conditions: Benign Essential Blepharospasm, Hemifacial Spasm | Phase 4 | Status: RECRUITING